分泌抗 EpCAM 双特异性 T 细胞衔接器的 CAR T 细胞克服靶向上皮来源癌时的肿瘤异质性
CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas.
嵌合抗原受体(CAR)T细胞疗法治疗实体瘤的成功有限,部分原因是肿瘤异质性和抗原逃逸。
FRONTIER PAPERS
CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas.
嵌合抗原受体(CAR)T细胞疗法治疗实体瘤的成功有限,部分原因是肿瘤异质性和抗原逃逸。
Advances in immunotherapies in ovarian cancer.
卵巢癌(OC)仍是最致命的妇科恶性肿瘤之一,且尽管近半数病例存在TIL(肿瘤浸润淋巴细胞)(TILs),免疫检查点抑制剂仅显示出有限的临床获益。
Dual-functional cationic hydrogel engineered for simultaneous prevention of postoperative tumor recurrence and wound infection.
术后复发和感染仍然是肿瘤切除后的主要挑战。
Coated oncolytic viruses based "double strike" strategy triggering CD19 CAR-T therapy in gastrointestinal tumors.
CAR-T(CAR-T)细胞疗法在实体瘤中的疗效受限于稳定抗原靶点的稀缺。
Cblb Gene Editing in T Cells Sustains Expansion and Immunogenic CAR T Tumor Killing Under Chronic Antigenic Stimulation.
CBL-B 是一种细胞内 E3 泛素连接酶,通过提高激活阈值和限制效应功能,充当 T 细胞检查点。
Next-generation T cell engagers for cancer and autoimmune diseases.
T细胞衔接抗体构建体(TCEs)已成为治疗癌症和自身免疫性疾病的一种有效手段。
Manufacturing and electrostatic surface optimization of CAR-T cells improve therapeutic efficacy in liver malignancies.
CAR-T 结构体的制造条件系统性优化与基于结构的电荷工程协同增强了对肝脏恶性肿瘤的治疗效果,为改善实体瘤 CAR-T 疗法提供了可转化的框架。
Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer.
这些发现表明 IMC001 在晚期胃癌中具有可接受的安全性和有前景的疗效,支持在难治性胃癌患者中进一步开展临床开发。
A spreadable self-gelling hemostatic powder sensitizes CAR-NK cell therapy to prevent hepatocellular carcinoma recurrence postresection.
过继性NK 细胞疗法(ANKCT)在对抗术后肝细胞癌(HCC)复发方面具有巨大潜力,但其疗效受到肿瘤微环境(TME)介导的NK细胞功能抑制以及NK细胞向肿瘤部位归巢不足的限制。
Chemotherapy driven alterations in NK cell receptors and ligands in high grade serous ovarian cancer.
我们的发现凸显了化疗对NK细胞受体、配体和细胞因子的广泛免疫调节作用,这可能为HGSOC的联合治疗提供见解。
MEMBER ACCOUNT
登录成功会直接打开下一页。